SE9701956D0 - New composition of matter - Google Patents

New composition of matter

Info

Publication number
SE9701956D0
SE9701956D0 SE9701956A SE9701956A SE9701956D0 SE 9701956 D0 SE9701956 D0 SE 9701956D0 SE 9701956 A SE9701956 A SE 9701956A SE 9701956 A SE9701956 A SE 9701956A SE 9701956 D0 SE9701956 D0 SE 9701956D0
Authority
SE
Sweden
Prior art keywords
treatment
particles
matter
new composition
budesonide
Prior art date
Application number
SE9701956A
Other languages
English (en)
Swedish (sv)
Inventor
Mikael Bisrat
Saeed Moshashaee
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9701956A priority Critical patent/SE9701956D0/xx
Publication of SE9701956D0 publication Critical patent/SE9701956D0/xx
Priority to IDW991396A priority patent/ID24332A/id
Priority to PL98336902A priority patent/PL336902A1/xx
Priority to NZ500852A priority patent/NZ500852A/en
Priority to DE69816997T priority patent/DE69816997T2/de
Priority to US09/091,453 priority patent/US6346523B1/en
Priority to SK1587-99A priority patent/SK158799A3/sk
Priority to EP98924697A priority patent/EP1005328B1/de
Priority to HU0002212A priority patent/HUP0002212A3/hu
Priority to CNB988053381A priority patent/CN1146406C/zh
Priority to PT98924697T priority patent/PT1005328E/pt
Priority to ZA984127A priority patent/ZA984127B/xx
Priority to ES98924697T priority patent/ES2205496T3/es
Priority to TR1999/02880T priority patent/TR199902880T2/xx
Priority to JP55028498A priority patent/JP2001525850A/ja
Priority to PCT/SE1998/000908 priority patent/WO1998052544A1/en
Priority to TW087107532A priority patent/TW518236B/zh
Priority to CA002290538A priority patent/CA2290538C/en
Priority to AU76800/98A priority patent/AU734763B2/en
Priority to AT98924697T priority patent/ATE246492T1/de
Priority to DK98924697T priority patent/DK1005328T3/da
Priority to BR9808812-2A priority patent/BR9808812A/pt
Priority to IL13309898A priority patent/IL133098A/xx
Priority to EEP199900533A priority patent/EE03850B1/xx
Priority to KR10-1999-7010785A priority patent/KR100514971B1/ko
Priority to ARP980102400A priority patent/AR015820A1/es
Priority to NO19995540A priority patent/NO995540L/no
Priority to IS5254A priority patent/IS5254A/is
Priority to US09/992,940 priority patent/US6468994B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9701956A 1997-05-23 1997-05-23 New composition of matter SE9701956D0 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE9701956A SE9701956D0 (sv) 1997-05-23 1997-05-23 New composition of matter
KR10-1999-7010785A KR100514971B1 (ko) 1997-05-23 1998-05-15 부데소니드의 미분 결정질 입자를 함유하는 조성물
ES98924697T ES2205496T3 (es) 1997-05-23 1998-05-15 Composicion que comprende particulas cristalinas de budesonida finamente divididas.
JP55028498A JP2001525850A (ja) 1997-05-23 1998-05-15 ブデソニドの粉砕した結晶粒子を含む組成物
NZ500852A NZ500852A (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide characterised in that they are smooth and have a BET value from 1-4.5m2/g
DE69816997T DE69816997T2 (de) 1997-05-23 1998-05-15 Mittel, die fein verteilte, kristalline budenosid-partikel enthalten
US09/091,453 US6346523B1 (en) 1997-05-23 1998-05-15 Budesonide particles and pharmaceutical compositions containing them
SK1587-99A SK158799A3 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide
EP98924697A EP1005328B1 (de) 1997-05-23 1998-05-15 Mittel, die fein verteilte, kristalline budenosid-partikel enthalten
HU0002212A HUP0002212A3 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide and preparation thereof
CNB988053381A CN1146406C (zh) 1997-05-23 1998-05-15 包含布地缩松细碎结晶颗粒的组合物
PT98924697T PT1005328E (pt) 1997-05-23 1998-05-15 Composicao compreendendo particulas de budesonido cristalinas finamente divididas
ZA984127A ZA984127B (en) 1997-05-23 1998-05-15 New composition of matter
IDW991396A ID24332A (id) 1997-05-23 1998-05-15 Komposisi yang mengandung partikel budesonida berbentuk kristal yang halus
TR1999/02880T TR199902880T2 (xx) 1997-05-23 1998-05-15 �nce par�alanm�� kristal budesonid par�ac�klar� i�eren kompozisyon
PL98336902A PL336902A1 (en) 1997-05-23 1998-05-15 Composition containing finely comminuted crystalline particles of budesonide
PCT/SE1998/000908 WO1998052544A1 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide
TW087107532A TW518236B (en) 1997-05-23 1998-05-15 Finely divided, substantially crystalline particles of budesonide, pharmaceutical composition comprising them and the preparation thereof
CA002290538A CA2290538C (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide
AU76800/98A AU734763B2 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide
AT98924697T ATE246492T1 (de) 1997-05-23 1998-05-15 Mittel, die fein verteilte, kristalline budenosid-partikel enthalten
DK98924697T DK1005328T3 (da) 1997-05-23 1998-05-15 Sammensætning omfattende findelte krystallinske partikler af budesonid
BR9808812-2A BR9808812A (pt) 1997-05-23 1998-05-15 Composição compreendendo partìculas cristalinas, finamente divididas de budesonida
IL13309898A IL133098A (en) 1997-05-23 1998-05-15 Composition comprising finely divided crystalline particles of budesonide
EEP199900533A EE03850B1 (et) 1997-05-23 1998-05-15 Budesoniidi peenestatud kristallilisi osakesi sisaldav ravimvorm
ARP980102400A AR015820A1 (es) 1997-05-23 1998-05-22 Particulas de budesonida, composicion farmaceutica, uso de dichas particulas para la fabricacion de medicamentos, metodo para el tratamiento de untrastorno respiratorio y proceso para la preparacion de las particulas
NO19995540A NO995540L (no) 1997-05-23 1999-11-12 Preparat omfattende findelte, krystallinske partikler av budesonid
IS5254A IS5254A (is) 1997-05-23 1999-11-18 Samsetning sem inniheldur fíngerðar, kristallaðaragnir af búdesóníð
US09/992,940 US6468994B2 (en) 1997-05-23 2001-11-06 Budesonide particles and pharmaceutical compositions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701956A SE9701956D0 (sv) 1997-05-23 1997-05-23 New composition of matter

Publications (1)

Publication Number Publication Date
SE9701956D0 true SE9701956D0 (sv) 1997-05-23

Family

ID=20407079

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9701956A SE9701956D0 (sv) 1997-05-23 1997-05-23 New composition of matter

Country Status (28)

Country Link
US (2) US6346523B1 (de)
EP (1) EP1005328B1 (de)
JP (1) JP2001525850A (de)
KR (1) KR100514971B1 (de)
CN (1) CN1146406C (de)
AR (1) AR015820A1 (de)
AT (1) ATE246492T1 (de)
AU (1) AU734763B2 (de)
BR (1) BR9808812A (de)
CA (1) CA2290538C (de)
DE (1) DE69816997T2 (de)
DK (1) DK1005328T3 (de)
EE (1) EE03850B1 (de)
ES (1) ES2205496T3 (de)
HU (1) HUP0002212A3 (de)
ID (1) ID24332A (de)
IL (1) IL133098A (de)
IS (1) IS5254A (de)
NO (1) NO995540L (de)
NZ (1) NZ500852A (de)
PL (1) PL336902A1 (de)
PT (1) PT1005328E (de)
SE (1) SE9701956D0 (de)
SK (1) SK158799A3 (de)
TR (1) TR199902880T2 (de)
TW (1) TW518236B (de)
WO (1) WO1998052544A1 (de)
ZA (1) ZA984127B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
RU2271851C2 (ru) 2000-03-03 2006-03-20 Бёрингер Ингельхайм Фармасьютиклз, Инк. Обработка материалов многократным расширением-сжатием растворителя
EP1354581A4 (de) * 2000-12-26 2007-07-04 Takeda Pharmaceutical Poröse substanz und verfahren zu ihrer herstellung
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
JP2004537401A (ja) 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション 疎水性薬物の微粉砕方法
DE60211004T2 (de) * 2001-10-10 2006-08-31 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Pulververarbeitung mit unter druck stehenden gasförmigen fluids
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP2007501683A (ja) 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ATE446581T1 (de) * 2004-03-12 2009-11-15 Trinity College Dublin Magnetoresistives medium
CN101312713A (zh) * 2005-03-18 2008-11-26 纳米材料科技有限公司 可吸入的药物
EP1904219A4 (de) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Teilchenbildungsverfahren
EP1782839A1 (de) 2005-11-03 2007-05-09 Genetic S.p.A. Verfahren zur Sterilisation von Glucocorticosteroiden mit überkritischem CO2
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
WO2007095341A2 (en) * 2006-02-15 2007-08-23 Tika Läkemedel Ab Sterilization of corticosteroids with reduced mass loss
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
EP2618816A4 (de) * 2010-09-22 2014-10-29 Map Pharmaceuticals Ltd Aerosol-zusammensetzung zur verabreichung von medikamenten
CN102975731B (zh) * 2012-04-24 2015-08-12 南车南京浦镇车辆有限公司 轨道车辆司机室骨架与车体的安装结构
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment
KR102567655B1 (ko) 2020-11-13 2023-08-17 주식회사 비츠로이엠 진공커패시터 및 진공커패시터 제조 방법
KR102739398B1 (ko) 2021-11-17 2024-12-06 주식회사 비츠로이엠 가변형 진공 커패시터
KR102739399B1 (ko) 2021-11-17 2024-12-06 주식회사 비츠로이엠 가변형 진공 커패시터의 나선형 전극 위치 결정구조

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
AU624421B2 (en) 1988-10-05 1992-06-11 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
DE69112917T2 (de) 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SG48301A1 (en) * 1991-12-18 1998-04-17 Astra Ab New combination
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles

Also Published As

Publication number Publication date
TR199902880T2 (xx) 2000-02-21
AR015820A1 (es) 2001-05-30
EP1005328A1 (de) 2000-06-07
BR9808812A (pt) 2000-07-18
DE69816997D1 (de) 2003-09-11
ID24332A (id) 2000-07-13
SK158799A3 (en) 2000-05-16
NZ500852A (en) 2001-07-27
IL133098A (en) 2005-03-20
ZA984127B (en) 1998-11-23
PT1005328E (pt) 2003-11-28
CA2290538C (en) 2007-01-02
US20020037257A1 (en) 2002-03-28
IS5254A (is) 1999-11-18
DE69816997T2 (de) 2004-07-22
TW518236B (en) 2003-01-21
ATE246492T1 (de) 2003-08-15
AU7680098A (en) 1998-12-11
EP1005328B1 (de) 2003-08-06
ES2205496T3 (es) 2004-05-01
DK1005328T3 (da) 2003-11-17
KR100514971B1 (ko) 2005-09-15
NO995540D0 (no) 1999-11-12
PL336902A1 (en) 2000-07-17
NO995540L (no) 1999-11-12
IL133098A0 (en) 2001-03-19
EE9900533A (et) 2000-06-15
EE03850B1 (et) 2002-10-15
CA2290538A1 (en) 1998-11-26
JP2001525850A (ja) 2001-12-11
HUP0002212A3 (en) 2001-04-28
CN1257424A (zh) 2000-06-21
US6468994B2 (en) 2002-10-22
HUP0002212A2 (hu) 2000-12-28
US6346523B1 (en) 2002-02-12
AU734763B2 (en) 2001-06-21
CN1146406C (zh) 2004-04-21
KR20010012821A (ko) 2001-02-26
WO1998052544A1 (en) 1998-11-26

Similar Documents

Publication Publication Date Title
CA2290538A1 (en) Composition comprising finely divided, crystalline particles of budesonide
PT937100E (pt) Nova forma polimorfica cristalina de propionato de fluticasona, um metodo para a sua producao e suas composicoes farmaceuticas
DE60121012D1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
ES8304797A1 (es) "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas".
ES2152394T3 (es) Composicion para inhalacion que contiene granulos de lactosa.
FI20002215A0 (fi) Yhdistelmäpartikkelit
GB9425160D0 (en) Medicaments
BE902185A (fr) Compositions pour les soins des voies respiratoires.
HK18695A (en) Inhalation medicaments for treating respiratory disorders
MX9605650A (es) Formulaciones de propionato de fluticasona.
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
IL110681A0 (en) Pharmaceutical compositions containing flupirtine for the treatment of neurodegenerative diseases
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
UA60352C2 (uk) Синтетичні полісахариди та фармацевтична композиція, що їх містить
EP0657167A3 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingt Störungen, pharmaceutische Zusammensetzungen die Oenothein B enthalten und ein Verfahren zu ihrer Herstellung von Epilobium Parniflorum.
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
DE69918961D1 (de) Verbesserte inhalationspräparate
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
IL109076A0 (en) Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them
IL168308A (en) Compositions containing roflumilast and formoterol
FR2673105B1 (fr) Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections.
UA88284C2 (ru) Твердая лекарственная форма, которая содержит действующее вещество из группы ингибиторов обратного захвата моноаминовых нейротрансмиттеров с 2,3-двухзамещенным тропановым скелетом, способ ее получения и применения
WO2005049024A3 (de) Feste pharmazeutische zubereitungsform
DK0950053T3 (da) Hidtil ukendte benzoylalkyl.1,2,3,6-tetrahydropyridinderivater